2020 has presented many challenges. But, through it all, we’ve been determined to support our employees, customers, and communities. Because of this, we are honored to be recognized by Forbes and JUST Capital in the #AmericasMostJUST and #1 spot for workers in the Pharmaceuticals and Biotech Companies.
We are joining a $100 M USD partnership to support the Africa Centres for Disease Control and Prevention (Africa CDC) in launching the Africa Pathogen Genomics Initiative (APGI), which will expand access to NGS, boosting pathogen surveillance across Africa.
We invite you to attend Illumina’s Consumer & Healthcare Genomics Virtual Summit on October 14. We will be addressing the global theme of “meeting the unmet need in genetic counseling”. To find out more and register, click here:
Our commitment to diversity, inclusion, and fairness in all that we do is a core part of our culture at Illumina. We’re thrilled to welcome Dr. Lisa Toppin as our new VP of Diversity & Inclusion (D&I) to help us continue that commitment in new and meaningful ways.
At Illumina, we firmly believe that no one should be paid differently because of their gender, race, age, ethnicity, sexual orientation or national origin. We continue to commit to global pay equity, and we are proud to have confirmed a zero gap in pay. Global pay equity is just one part of Illumina’s ongoing commitment to diversity, inclusion and fairness in all we do across the company.
We are excited to announce our agreement to acquire GRAIL, Inc., the company detecting cancer early with a simple blood test. Beating cancer begins with finding it. Together we have the opportunity to revolutionize cancer testing & support our mission to improve human health.
A little more than three years after debuting the NovaSeq 6000, we installed our 1,000th system. The sequencer was installed at the Whitehead Institute for Biomedical Research in Cambridge, Massachusetts. We?re making deeper discoveries more accessible than ever.
Genomic insights can potentially transform human health and everyone should have the opportunity to benefit from the power of precision medicine. How are we breaking down barriers to ensure access for all? Read more.
Announcing the NovaSeq 6000 v1.5 Reagent Kit offering accelerated access to exceptional discovery power and operating efficiency, unlocking high throughput applications at our best price ever. The power to make bigger discoveries is yours with the new NovaSeq 6000 v1.5 Reagent Kit. Significantly improved sequencing costs allow greater access to data-rich applications like single-cell, WGS, liquid biopsy, and more. The kits not only offer improved economics, but also feature enhancements such as extended shelf life, fully supported UMIs, increased quality specifications score, and support for new Library Prep kits and assays. It?s your reagent kits, reimagined.
COVID-19 testing is a vital part of a confident return-to-school plan, and we are proud to be involved in Testing for America's work to bring students back to HBCUs this fall.